The Federal Trade Commission is backing pharmaceutical company Mylan Pharmaceuticals, based in Pennsylvania, in its efforts to bring charges against Warner Chilcott Plc, whose headquarters reside in New Jersey. Three class action suits have been filed against Warner Chilcott in addition to Mylan’s suit, which alleges that Warner Chilcott was hampering competition by preventing Mylan from selling a generic antibacterial drug. While the drug is made by Warner Chilcott, Mylan says that Warner Chilcott was preventing the sale of the generic and instead pushing for the sale of another version of the drug that Warner Chilcott sells itself, which Mylan says was different but not “better.”
Full Content: Philly.com
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI